Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (3910)	4/21/2015 9:06:14 AM
From: richardred	1 Recommendation Recommended By The Ox Respond to of 7254

This is getting interesting. Shares of drugmaker Mylan are going wild after getting a buyout proposal Wikimedia Commons Shares of Mylan pharmaceuticals spiked by more than 10% in pre-market trading after it received a buyout proposal from Teva pharmaceuticals. Teva proposed to buy Mylan for $82 per share in cash and stock, according to a statement. Erez Vigodman, CEO of Teva, said: “Our proposal would provide Teva stockholders with very attractive strategic and financial benefits and Mylan stockholders with a substantial premium and immediate value for their shares, as well as the opportunity to participate in the significant upside potential of the combined company – one that would transform the global generics space and leverage it to hold a unique leadership position in the pharmaceutical industry." An earlier report from Bloomberg suggested the deal would be announced today. Teva shares rose by more than 3% in pre-market trading. Teva's statement also said the proposal offers a better alternative to Mylan’s proposed acquisition of Perrigo, announced earlier this month. Mylan offered to buy Perrigo for $205 per share in a deal worth $28.9 billion. Mylan’s chairman Robert Coury had released a statement last week on initial reports of the deal, calling them "media speculation," and saying the company "is fully committed to its stand-alone strategy, including its proposal to acquire Perrigo, and today's speculation has no impact whatsoever on this strategy." There have already been a number of huge buyout offers and deals among pharmaceuticals and biotechs this year. And late last month, Teva Pharmaceuticals announced it will acquire Auspex Pharmaceuticals at $101 per share in cash. Read more: businessinsider.com